Navigation Links
FDA Approves Zytiga for Late-Stage Prostate Cancer
Date:4/28/2011

SILVER SPRING, Md., April 28, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Zytiga (abiraterone acetate) in combination with prednisone (a steroid) to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

In prostate cancer, the male sex hormone testosterone stimulates prostate tumors to grow. Drugs or surgery are used to reduce testosterone production or to block testosterone's effects. However, sometimes prostate cancer can continue to grow even when testosterone levels are low. Men with these cancers are said to have castration-resistant prostate cancer.

Zytiga is a pill that targets a protein called cytochrome P450 17A1 (CYP17A1) which plays an important role in the production of testosterone. The drug works by decreasing the production of this hormone that would stimulate cancer cells to continue growing.

The application was reviewed under the FDA's priority review program, which provides for an expedited six-month review for drugs that may offer major advances in treatment, or provide a treatment when no adequate therapy exists. Zytiga is being approved ahead of the product's June 20, 2011 regulatory goal date.

"Zytiga prolonged the lives of men with late-stage prostate cancer who had received prior treatments and had few available therapeutic options," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research.

Zytiga's safety and effectiveness were established in a clinical study of 1,195 patients with late-stage castration-resistant prostate cancer who had received prior treatment with docetaxel chemotherapy. Patients received either Zytiga once daily in combination with prednisone two times a day or a placebo (sugar pill) twice daily in combination with prednisone.

The study was designed to measure overall survival, the length of time from when the treatment started until a patient's death. Patients who received the Zytiga and prednisone combination had a median overall survival of 14.8 months compared to 10.9 months for patients receiving the placebo and prednisone combination.

The most commonly reported side effects in patients receiving Zytiga included joint swelling or discomfort, low levels of potassium in the blood, fluid retention (usually of the legs and feet), muscle discomfort, hot flashes, diarrhea, urinary tract infection, cough, high blood pressure, heartbeat disorders, urinary frequency, increased nighttime urination, upset stomach or indigestion and upper respiratory tract infection.

Zytiga is marketed by Horsham, Pa.-based Centocor Ortho Biotech, Inc.

For more information:

FDA: Office of Oncology Drug Products

http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

FDA: Approved Drugs: Questions and Answers

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

NCI: Prostate Cancer

http://www.cancer.gov/cancertopics/types/prostate

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
2. FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
3. FDA Approves the First Vaccine to Prevent Meningococcal Disease in Infants and Toddlers
4. FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis
5. FDA Approves New Medical Device for Form of Brain Cancer
6. FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors
7. FDA Approves Horizant To Treat Restless Legs Syndrome
8. FDA Approves New Treatment for Rare Form of Thyroid Cancer
9. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
10. FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
11. FDA Approves New Treatment for a Type of Late-Stage Skin Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... -- Boston Scientific Corporation (NYSE: BSX ) today ... privately-held Swiss structural heart company focused on minimally-invasive transcatheter ... The Symetis portfolio includes the ACURATE TA™ ... for use in the treatment of high-risk patients suffering ... sold in Europe and in ...
(Date:3/30/2017)... March 29, 2017 The new ... browse a comprehensive collection of company reports on ... and analysis of their activities in the healthcare industry. ... ... healthcare industry is going through a fundamental transformation globally-a ...
(Date:3/30/2017)... Research and Markets has announced the addition of ... By Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, Consumables, Services), ... 2025" report to their offering. ... The global hemodialysis and ... by 2025. Home-based dialysis treatment is ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... ... from Greet, S.C., wants to offer people a new way to care for their feet. ... so I know the importance of proper foot care," he said. "In order to enable ... The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the bottoms of his or ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, a leader in ... Hospital Readmissions Through Discharge Planning ” with noted expert Sue Dill Calloway, RN, ... discusses strategies to prevent readmissions in light of the most recent programs at ...
(Date:3/29/2017)... Provo, Utah (PRWEB) , ... March 29, 2017 , ... ... an event to provide free screening colonoscopies to eligible individuals in the local community. ... and the U.S., but regular screenings can detect colon cancer while it is small, ...
(Date:3/29/2017)... ... , ... In the United States alone, up to 36% of primary brain ... metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are known to ... treatment options, the San Diego Gamma Knife Center offers a precision-medicine based ...
(Date:3/29/2017)... ... ... Full Contact K9, an Atlanta-based dog services provider, has recently teamed up ... owners in creating legally-enforceable pet trusts for their canine companions. , Therilus, a ... their new companion. Says Evan Dunbar, CEO of Full Contact K9, “When our clients ...
Breaking Medicine News(10 mins):